Clinical trial
AMA1-C1/Alhydrogel + CpG 7909 for Malaria
NCT00344539 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00344539 |
|---|---|
| Title | AMA1-C1/Alhydrogel + CpG 7909 for Malaria |
| Official title | Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Plasmodium Falciparum Malaria |
| Intervention type | Biological |
| Interventions | AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®) |
| Enrollment | 75 |
| Start date | May 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Jun 26, 2006 |
| Last update posted | Jun 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: